| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.16 | 5e-07 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | 0.16 | 7e-07 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.16 | 8e-07 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-06 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | 0.13 | 3e-06 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | 0.19 | 3e-06 |
| mRNA | SCH-79797 | CTRPv2 | pan-cancer | AAC | 0.17 | 3e-06 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.15 | 4e-06 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.15 | 4e-06 |
| mRNA | SN-38 | CTRPv2 | pan-cancer | AAC | 0.17 | 5e-06 |